Welcome to LookChem.com Sign In|Join Free
  • or
(E)-ethyl 2-(2-(3-nitrophenyl)hydrazono)propanoate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1056933-72-2

Post Buying Request

1056933-72-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1056933-72-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1056933-72-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,6,9,3 and 3 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1056933-72:
(9*1)+(8*0)+(7*5)+(6*6)+(5*9)+(4*3)+(3*3)+(2*7)+(1*2)=162
162 % 10 = 2
So 1056933-72-2 is a valid CAS Registry Number.

1056933-72-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name (E)-ethyl 2-(2-(3-nitrophenyl)hydrazono)propanoate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1056933-72-2 SDS

1056933-72-2Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

-

Paragraph 0398; 1745, (2015/09/22)

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

-

, (2012/04/23)

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

-

Page/Page column 138-139, (2008/06/13)

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

N-Benzylindole-2-carboxylic acids: Potent functional antagonists of the CCR2b chemokine receptor

Kettle, Jason G.,Faull, Alan W.,Barker, Andy J.,Davies, D. Huw,Stone, Michael A.

, p. 405 - 408 (2007/10/03)

Screening of the corporate database led to the discovery of a novel series of N-benzylindole-2-carboxylic acid CCR2b chemokine receptor antagonists. These compounds demonstrate high affinity and functional inhibition of the CCR2b receptor. A discussion of

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1056933-72-2